Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

NCT01554618 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01554618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01554618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents With Type 2 Diabetes
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
December 2, 2011
Completion date
May 5, 2021
Enrollment
84 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

children and adolescent with type 2 diabetes